Six novel spirodihydrobenzofuranlactams I~VI (1~6) and a related spirodihydrobenzofuranalcohol, the previously described natural compound L-671,776 (7), were isolated from cultures of two different Stachybotrys species. These secondary metabolites showedantagonistic effects in the endothelin receptor binding assay and inhibited HIV-1 protease. Both biological activities are novel for L-671,776 (7). The pseudosymmetric spirodihydrobenzofuranlactam VI (6) is the most potent representative of this class of compoundsexhibiting IC50 values of 1.5^m in the ET-Areceptor binding assay and ll jjm in the HIV-1 protease inhibition assay.
Six novel spirodihydrobenzofuranlactams I~VI (1~6) and a related spirodihydrobenzofuranalcohol, the previously described natural compound L-671,776 (7), were isolated from cultures of two different Stachybotrys species. These secondary metabolites showedantagonistic effects in the endothelin receptor binding assay and inhibited HIV-1 protease. Both biological activities are novel for L-671,776 (7). The pseudosymmetric spirodihydrobenzofuranlactam VI (6) is the most potent representative of this class of compoundsexhibiting IC50 values of 1.5^m in the ET-Areceptor binding assay and ll jjm in the HIV-1 protease inhibition assay.
Endothelin-1 (ET-1), a 21 amino acid peptide, demonstrates potent vasoconstrictor, mitogenesis and bronchoconstrictor activity1~3). Previous studies have indicated that at least two distinct endothelin receptor subtypes exist, the ET-A and ET-B receptors4'5).
Identification of novel compoundsthat inhibit the ability of ET-1 to bind to these receptors may lead to novel treatments for hypertension, congestive heart failure, asthma or atherosclerosis6). The protease of Human Immunodeficiency Virus (HIV) has been proven to be essential for correct processing of the viral gag and gag-pol precursor proteins7). Inhibition of this enzyme led to the formation 13 of non infectious progeny virus in vitro. Therefore this enzymehas attracted the interest of the pharmaceutical research community aiming to identify enzyme inhibitors with antiviral activity, which would be valuable as anti-AIDS agents. Unfortunately most compounds identified as first generation inhibitors belonged to the class of peptidomimetics and displayed only low oral bioavailability8). Therefore programs to screen extracts from natural sources were initiated which were hoped to lead to the discovery of substances with improved oral bioavailability.
In the course of a screening program for antagonists of endothelin receptor binding and for inhibitors of HIV-1 protease a Stachybotrys chartarum strain was found which produced the known spirodihydrobenzofuranalcdhol L-671 ,776 (7)9), and the spirodihydrobenzofuranlactams II , III, IV and VI (2, 3, 4, 6) (Scheme 1). The spirodihydrobenzofuranlactam I (1) and its imide (5) were isolated from a different fungal strain Stachybotrys atra F11402. The lactams 1~4, 6 and the imide 5 form a novel class of compounds of the spirodihydrobenzofuran family, while L-671,776 has already been patented as an inositol-phosphate phosphatase inhibitor9) isolated from Memnoniella echinata and is structurally related to K-761O) and to the recently described avian myeloblastosis virus protease (AMV) inhibitors Mer-NF5003B, E and F11}.
In this article the cultivation of the producing microorganisms, as well as the isolation and biological activities of the natural products 1~7 are described.
Materials and Methods Microorganisms: Isolation and Preservation
The fungal strain DSM8767 was isolated from a soil sample collected at the Lake Kokonos, China. The fungus was taxonomically classified as Stachybotrys chartarum and has been deposited with the DSM (Deutsche Sammlung fur Mikroorganismen und Zellkulturen, Braunschweig, Germany). The microorganism was grown on LCSBagar (Lactose 1.5%, cornsteep liquor 0.5%, peptone 0.5%, NaCl 0.4%, MgSO4x7 H2O 0.05%, KH2PO4 0.06%, FeCl3x6 H2O 0.0005%, CuSO4x5 H2O 0.0002%, agar 3.0%). The pH was adjusted to 4.8 with 5n H2SO4 or 5n NaOH. The fungus was incubated at 28°C for ten days until complete sporulation had occured. Workingstocks are stored at 4°C, whereas long-term storageis at -80°C and -196°C, respectively.
The strain Fl 1402 was isolated from a piece of wood collected in Sarno, Italy, and has been classified as a representative of the species Stachybotrys atra. This fungus was cultivated on slopes prepared of mycophil agar (BBL) at 25°C for ten days. The working stocks and the long-term preservation were carried out as described above. The species names Stachybotrys chartarum and Stachybotrys atra are synonyms, named by S. Hughes respectively Corda. The colony characteristics were growth on oat flake agar about 2mm/day at 25°C, colorless mycelium, sparse aerial mycelium, conidial masses in blackish drops, reverse uncolored, no exudate, irregular and slow growth on malt extract and maximum growth temperature between 37°C and 40°C. The micromorphology showed conidiophores that were mostly simple, partly branched, 100/mi long and with a diameter of 3~6//m, and were colorless at the base, but darkening and roughening to the apex. A cluster of JAN. 1996 ellipsoidal phialides was formed at the apex, the phialides were 10^12/im long. Conidia aggregated into slimy masses, were ellipsoidal, had a dimension of 10 x 6ium and were smooth-walled to coarsely roughened.
Fermentation
A mature slant culture of the strain DSM8767 was inoculated into a 500ml Erlenmeyer flask with 1 baffle containing 100ml of a medium with the following composition: Glucose 2.0%, Pharmamedia 1.5%, (NH4)2SO4 0.3%, ZnSO4-7H2O 0.003%, CaCO3 0.4%. Before sterilization, the pH was adjusted to 7.0. The culture was shaken under aerobic conditions for 48 hours at 28°C and 250rpm. 5ml of the seed culture were transferred into 500 ml of the above medium in a 2,000 ml Erlenmeyer flask with four baffles. The vegetative culture was incubated under the same conditions as already described. 5.0% of the second seed culture was transferred into a 50 liter fermenter filled with 30 liters of the following production medium: Glucose 1.0%, potato starch 3.0%, casamino acids (Difco) 0.5%, LabLemco (Oxoid) 0.3%, yeast extract (Difco) 0.2%, N-Z Amine
0.05%, KC1 0.03%, CaCO3 0.3%. Before sterilization, the pH was adjusted to 7.0. The aeration rate was 30liters/minute and the agitation rate was adjusted to 600 rpm. A typical fermentation profile of the strain Stachybotrys chartarum DSM8767 is shown in Fig. 1 . The cultivation was performed in a 3.5-liter fermenter (MBR) at 28°C for 192 hours with an aeration rate of 1liter/ minute and an agitation rate of 700 rpm. The preculture conditions have already been described above. The fermenter was filled with 1 liter of the previously mentioned production medium.
For the cultivation of Stachybotrys atra F11402, a piece of a well sporulated culture thereof was inoculated into a 500 ml Erlenmeyer flask with one baffle, filled with 100 ml ofa medium which had the following composition: (3), (4), (6) and (7) in a 3.5-liter fermenter.
+ (3), aef (4), å (6), O (7), ApH, à" pO2. The incubation was carried out at 25°C and a rotation rate of 250rpm. After 48 hours, 5.0% of the culture broth was used for inoculation of a second preculture with the samemedium.
2,000 ml Erlenmeyer flasks with four baffles were filled with 500ml of the described preculture medium. The cultivation was performed for 48 hours at 28°C with 125 rpm. For the production of the compounds 1 and 5, 5.0% of the preculture were transferred into an 50 liter fermenter filled with the following production medium: Potato starch 6%, soybean meal (defatted) 2%, K2HPO4 0.03%. Before sterilization, the pH was adjusted to 6.4. The aeration rate was 30 liters/minute and the agitation rate was at 600rpm. Stachybotrys chartarum DSM8767 (Scheme 2) the whole broth (120 liters) was mixed with EtOAc (240 liters). Subsequent filtration was performed using a filter aid (Celite; Celite Corp., U.S.A.). The aqueous and organic phases were separated, the aqueous phase was discarded, while the organic layer was washedwith sodium chloride solution (20%, 9.8 liters) and concentrated in vacuo. The EtOAc-extract was partitioned between heptane (620 ml) and aqueous CH3OH(10%, 770ml). Crude L-671,776 (7) (21.8 g) was purified in portions (1~2g) by reversed phase preparative HPLCwith H2O as mobile phase A and CH3CN-H2O80:30 (v/v) as mobile phase B. The flow rate of the mobile phase was 30ml/minute. A gradient was run from 50% to 100% phase B in 80 minutes with the detection wavelength set to 235nm. The starting material (2.1 g) was suspended in 3ml CH3OH and applied to the above described reversed phase column. L-671,776 (7) (1.2g) eluted from 68% to 100% mobile phase B.
The crude mixture of the spirodihydrobenzofuranlactams II, III, IV and VI (2, 3, 4, 6) which eluted with CH2C12 -CH3OH50 : 50 (v/v) from the silica gel column, was further purified in portions (0.8~1.5 g) by reversed phase preparative HPLCwith H2Oas mobile phase A and CH3CN-H2O80:20 (v/v) as mobile phase B and a flow rate of 20ml/minute. A gradient was run from 75% to 100%phase B in 80 minutes with the detection wavelength set to 235 nm. The starting material (0.86 g) was suspended in 3 ml CH3OH and applied to the above described reversed phase column. Pure compound 2 (21 mg) eluted with 82%mobile phase B, a mixture of 3 and 4 (83mg) eluted from 83% to 84% phase B and pure metabolite 6 (105mg) eluted from 87% to 92% mobile phase B. A mixture of 3 and 4 (83 mg) was rechromatographed on reversed phase running a gradient from 10% to 80% phase B in 80 minutes. 83mg of crude 3 and 4 were suspended in 0.3 ml CH3OHand applied to the reversed phase column. Pure compound 4 (5 mg) eluted with 50% to 62%mobile phase B, while pure compound3 eluted from 64% to 75% phase B.
For the work-up of Stachybotrys atra Fl 1402 cultures (Scheme 3) the whole broth (90 liters) was lyophilized. CH3OHextract was suspended in H2O, the pH value was adjusted to 2.5 with 5n sulfuric acid and extracted with EtOAc (30 liters). The aqueous and organic phases were separated, the aqueous phase was discarded, while the organic layer was concentrated in vacuo yielding 1 88 g of crude extract. The crude extract (188 g) was purified by gel filtration on Sephadex LH-20 using as mobile phase. Enriched compound 5 (8.7g) eluted after 4.7 liters mobile phase and crude 1 (10g) after 5 liters CH3OH-CH2C12 50 : 50 (v/v).
Enriched 1 was further purified on silica gel using CH2C12-isopropanol as mobile phase. Compound 1 (10g), dissolved in CH2C12, was applied to the column and eluted with CH2C12-isopropanol 90: 10 (v/v).
Recrystallisation from EtOAc (150ml) yielded pure 1 (5.9g).
In analogy to the separation of 1 crude compound5 was further purified by silica gel chromatography using Normal rat kidney (NRK) cells, which were used as the source of ET-Areceptors, were scraped and transferred to a conical centrifuge bottle (250ml) on ice. The cells were rinsed with 10ml TE8 buffer (10mM Tris-NaOH, 1 mMEDTA, pH 8.0) with 1 mMDTT and then homogenized using a Polytron for 10 seconds at setting 6. PMSF (0.1m, 10^1/ml) was added and the cells were centrifuged at 1000 x g for 10 minutes. The supernatant was centrifuged at 48000 x g for 10 minutes. The pellets were resuspended in 5ml HBSS(Ca+ +/Mg+ + free) per flask of cells. Cells were stored in 1 ml aliquots at -80°C until assay.
On the day of the experiment, membranepreparations (18.5jUg/ml protein for NRK cells) were thawed and suspended in 20mMHepes buffer, pH 7.4, containing JAN. 1996 145himNaCl, 5himKC1, 1 himCaCl2, 1 himMgCl2, 0.1% bovine serum albumin and 0.02% bacitracin. Binding experiments were performed by incubating 100^1 of the suspension, 50/d of either 10pM [125I] ET-1 (NEN-Du Pont, Boston, MA; specific activity 2200 Ci/mmol) and 50iA of drug or buffer at a final volume of0.5ml for 90 minutes (NRK cells) at 37°C. Non-specific binding was determined in the presence of 100nMunlabeled ET-1. Boundand free radioactivity were separated by vacuum filtration through WhatmanGF/C glass fiber filters presoaked in 2%powdered milk. Filters were washed three times in 4ml of ice-cold buffer and counted in a Genesys gammacounter (Schaumburg, IL). HIV protease assay: During the purification procedure the anti-HIV-1 protease activity was monitored using the scintillation proximity assay12) (HIV Proteinase 125I SPA Enzyme Assay System (IMK 8939); Amersham International Pic, Cardiff, UK). All fractions and pure compounds were solubilized in DMSO(final concentration < 5him). The IC50 values for compound 1 to 7 were determined by a peptide-based enzyme assay: The cleavage of the icosapeptide RRSNQVSQNY*PIVQ-NIQGRR(164/jm) in 20mM MES(morpholinoethanesulfonic acid; pH 6.0) was monitored. The reaction was started by the addition of E. coli expressed and purified HIV-1 protease13). After 60 minutes incubation at 37°C the reaction was stopped by adding HC1O4to a final concentration of 0.03^m and product formation was analyzed by RP-HPLC14).
Results and Discussion
The time course for the production of the three novel spirodihydrobenzofuranlactams III, IV and VI (3, 4, 6) and the related spirodihydrobenzofuran alcohol L-671,776 (7) was determined by experiments in a 3.5 liter fermenter and was monitored by HPLC-analysis ( Fig.   1 ). It could be shown that L-671,776 (7) is a biosynthetic precursor of the spirodihydrobenzofuranlactams 3, 4 and 6. After 48 hours of fermentation the highest titer of L-671,776 (7) was achieved. In parallel to the titer decrease of L-671,776 (7) the production of the spirodihydrobenzofuranlactams increased as could be monitored by HPLC-analysis of the culture broth after different incubation times (Fig. 1) .
Cultures of the Stachybotrys chartarum DSM8767 strain were worked up after 120 hours of fermentation time. The extraction of the whole broth of the Stachybotrys chartarum DSM8767 by EtOAc and the partitioning of the organic phase between heptane and 10% aqueous CH3OHyielded crude extract containing L-67 1 ,776 (7) and the spirodihydrobenzofuranlactams II, III, IV, and VI (2, 3, 4, 6 The spirodihydrobenzofuranalcohol L-671,776 (7) is knownas an inositol-phosphate phosphatase inhibitor9). However, its weak endothelin activity and the moderate inhibiting activity against HIV-1 protease are new biological properties of this compound, which have not been reported previously. In addition it could be shown that L-671,776 (7) is an important precursor of the most interesting representative of the spirodihydrobenzofuran family, the metabolite 6. In conclusion the six spirodihydrobenzofuranlactams I-VI (1~6) represent a novel class of biologically active natural products. Hexapeptides16) and pentapeptides1 7)
have been reported as naturally occurring antagonists of endothelin. Recently the sesquiterpene S-50-23518) has been isolated as another natural antagonist from the plant Myrica cerifera, but the spirodihydrobenzofuranlactams are structurally unique antagonists of endothelin.
